Pharma Mar SA (PHMR.MC)
15 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|President, Chief Executive Officer, Executive Chairman of the Board|
|Executive Vice Chairman|
|Chief Financial Officer|
|Director of Human Resources and IT|
|2011||Vice President - Medical Affairs|
- BRIEF-Pharma Mar Says CHMP Against Approving MAA Of Aplidin For Multiple Myeloma Treatment
- BRIEF-Pharma Mar Presents Positive Phase III Trial Results Of Plitidepsin In Multiple Myeloma
- BRIEF-Pharma Mar says IDMC recommends Phase III trial with Zepsyre in small-cell lung cancer patients to continue
- BRIEF-Pharma Mar presents positive results from phase II study of lurbinectedin in Ewing's sarcoma
- BRIEF-Pharma Mar expects EMA not to approve its Aplidin for multiple myeloma treatment